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Background: Despite screening blood donations with advanced technologies and improved donor screening, the
risk of transfusion-transmitted infections persists. This risk is mainly due to blood donations collected during the
window period. A precise estimate of the transfusion risk of viral infection will help to determine the effect of new
and current safety measures and to prioritize and allocate limited resources. Therefore, we estimated the risk of
transfusion-transmitted viral infection in blood donations collected in Korea from 2000 to 2010.
Methods: Blood donations collected at 16 blood centers were tested for HIV, HCV, and HBV to estimate the
residual risk of transfusion-transmitted viral infection. The residual risk was calculated in two-year periods using the
incidence/window model. The incidence rates for HIV/HCV and the confirmed positive rate for HIV/HCV in first-time
and repeat donors were compared.
Results: The residual risks for HIV in 2004/2005 and 2009/2010 were 1 in 1,080,244 and 1 in 1,356,547, respectively.
The risks for HCV in 2000/2001 and 2009/2010 were 1 in 81,431 and 1 in 2,984,415, and the risks for HBV in
2000/2001 and 2009/2010 were 1 in 45,891 and 1 in 43,666. These estimates indicate that the residual risks for HCV
in Korea have declined 36.6-fold, and those for HIV and HBV have not improved significantly, compared to previous
estimates. The odds ratios for HCV and HBV positivity in first-time donors compared to repeat donors were 11.8 and
19.6, respectively.
Conclusions: The residual risk of HCV declined over the last decade due to improved screening reagents,
implementation of the nucleic acid amplification test, and tight application of strict donor selection procedures.
Current residual risk estimates for HIV and HCV in Korea are extremely low, but the risk for HBV is still high;
therefore, urgent measures should focus on decreasing the residual risk of HBV. Despite the introduction of more
sensitive assays in blood screening, several other factors may influence the actual residual risk of
transfusion-transmitted infection. A continuous monitoring of residual risk of transfusion-transmitted infection
is crucial in managing blood safety.
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Table 1 Length of the window period for test reagents
Length of window period (days)
Estimate Range
HIV
anti-HIV(EIA) 22* 6~38
HIV-NAT 11*
HCV
anti-HCV(EIA) 66† 38~94
HCV-NAT 10{
HBV
HBsAg(EIA) 59} 37~87
HBsAg(CLIA) 45}
*Data were obtained from Busch et al. [3].
†Data were obtained from Courouce et al. [6].
{Data were obtained from Dodd et al. [7].
}Data were obtained from Mimms et al. [4].
}Data were obtained from Comanor et al. [5].
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The realization that human immunodeficiency virus
(HIV) can be transmitted through transfusion mobilized
huge public concern for blood safety in the 1980s. Test-
ing donations with advanced technologies and excluding
donors at high risk of infection have reduced the risk of
infectious donations entering the blood supply. The risk
of transfusion-transmitted infection persists, however,
mainly due to blood donations collected during the win-
dow period.
A precise estimate of the transfusion risk of viral infec-
tion will help to monitor transfusion safety, to assess the
value of new screening interventions, to analyze the
effects of current safety measures, and to assist in devel-
oping public health policy. Furthermore, an accurate es-
timate of residual risk can help inform evidence-based
decisions in terms of prioritizing limited resources for
hepatitis B virus (HBV), which is more prevalent in
Korea than in countries such as the United States,
Canada, the UK, and some other European nations.
Current estimates of the residual risks of transfusion-
transmitted infection with HIV, hepatitis C virus (HCV),
and HBV in Korea are drawn from old studies that only
examined donors for short periods of time [1]. There-
fore, we estimated the risk of HIV, HCV, and HBV in
blood donations collected in Korea between 2000 and
2010. This information may be useful in adapting the
national policy for blood transfusion, as well as in decid-
ing among interventions targeted at blood safety.
Methods
Estimates of the residual risk of transfusion-transmitted
viral infection were based on the incidence/window
model [2]. All donations collected between January 2000
and December 2010 at the Korean Red Cross Blood
Center were included in this study. Data included the
number of blood donations, the number of donors who
donated blood at least twice during each two-year
period, the sum of intervals (in days) between the first
and last donation for each donor, the number of donors
that made a negative blood donation followed by a posi-
tive donation (seroconvertors), the sum of intervals (in
days) between the positive and negative donations for
seroconvertors, the number of confirmed positive dona-
tions, the screening assays, the methods used to confirm
donations, and donation history.
Donors were classified as first-time (donors not known
to have previously donated blood) or repeat donors
(donors who had donated blood before).
Incidence rates were calculated for donors who
donated at least twice during each two-year period. The
number of incident cases (numerator) was the number
of donors who gave a negative donation followed by a
confirmed positive blood donation. The window periodsfor anti-HIV, HIV-NAT, anti-HCV, HCV-NAT, and
HBsAg (EIA, CLIA) were obtained from previous
reports (Table 1) [3-7]. The incidence rate for each virus
was multiplied by the length of the window to calculate
the residual risk of infection [4,6-8].
All donations were screened for anti-HIV, anti-HCV,
and HBsAg using the assays listed in Table 2. Enzyme
immunoassays were used for anti-HIV and anti-HCV.
Samples were considered confirmed positive for anti-
HIV if they were reactive by Western blot and for anti-
HCV if they were reactive by immunoblot.
In February 2005, the Korean Red Cross introduced
NAT to screen blood donations for HIV-RNA and HCV-
RNA. HIV-NAT and HCV-NAT were performed on a
minipool of twenty-four samples using the AmpliScreen
HIV-1/HCV test (Roche Diagnostics, Branchgurg, NJ,
USA) on the Cobas Amplicor, combined with the Orga-
non Nuclisens extractor or on a minipool of sixteen
samples using the Procleix HIV-1/HCV assay (Chiron/
Gen-Probe, Emeryville, CA, USA). Approximately 18.2 mil-
lion allogeneic donations were screened for HIV-1 and HCV
by the Roche COBAS AmpliScreen assay, whereas the
Gen-Probe transcription-mediated amplification system
was used to screen approximately 7.8 million donations.
RNA was extracted from the plasma pools and screened
for HIV-1 RNA and HCV RNA by the COBAS AmpliSc-
reen HIV-1 and HCV test, v2.0. If a 24-member pool
tested reactive, further testing was performed on for 6-
member secondary pools. If a secondary pool tested
reacted, its 6 members were tested individually using the
COBAS AmpliScreen HCV test, v2.0. The NAT for HIV-1
and HCV was performed on 16 mini-pool of donor
plasma. A repeatedly reactive sample was tested with the
HIV-1 and HCV discriminatory assay (Procleix TMA
Table 2 Donor screening tests for HIV, HCV, and HBV from 2000 to 2010
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
HIV
anti-HIV (EIA) DA* DA DA GC† GC LG/GC{ LG/GC LG/BioRad LG/BioRad LG LG
HIV-NAT Roche/Chiron Roche/Chiron Roche/Chiron Roche/Chiron Roche/Chiron Roche/Chiron
HCV
anti-HCV (EIA) LG/SI} LG/SI LG/SI LG LG/DA SI/LG LG LG LG LG LG
HCV-NAT Roche/Chiron Roche/Chiron Roche/Chiron Roche/Chiron Roche/Chiron Roche/Chiron
HBV
HBsAg (EIA/CLIA) DA/
GC
DA/GC DA/GC GC/DA GC GC/LG BioRad/SI Abbott Abbott Abbott Abbott
*DA, Dong-A Pharm.
†GC, Green Cross co.
{LG, LG Corp.
}SI, Samil co. LTD.
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(HIV-1 and/or HCV) present.
Since July 2007, the Korean Red Cross has screened all
blood donations using the chemiluminescence immuno-
assay (CLIA) (Abbott Laboratories, Diagnostic Division,
Abbott Park, IL, USA) for HBsAg. Since the implemen-
tation of CLIA in July 2007, the number of confirmed
HBV cases was estimated from the confirmatory rate
(87.5%) of HBsAg among Korean blood donors using a
HBsAg neutralization test (PRISM, Abbott Diagnostics,
Chicago, IL, USA) [9]. Since the HBV-NAT was not
introduced yet, only HBsAg samples with a signal-to-
cutoff ratio (S/CO) equal to or greater than 6.00 were
considered as confirmed positive to exclude the false
positivity of neutralization test [10].
The NAT window period for HIV was used after the
introduction of NAT. The window period of anti-HCV
was used to calculate the residual risk for HCV until the
introduction of HCV-NAT. After the implementation of
NAT system, the NAT window period for HCV was used
to calculate the residual risk for HCV. The window
period of HBsAg enzyme immunoassay was used to cal-
culate the residual risk for HBV until the implementa-
tion of CLIA. After the implementation of CLIA, the
window period of HBsAg CLIA was used.
In the transition periods, which are 2004/2005 for HIV
and HCV and 2006/2007 for HBV, the weighted averages
of the two window periods adjusted by length of time
were used to calculate the residual risk for HIV, HCV,
and HBV.
The number of true seroconvertor was calculated
using the positive predictive value of HBsAg (EIA) be-
fore the implementation of CLIA. The positive predictive
value (PPV) of HBsAg (EIA) was calculated as 25.0%
based on the prevalence of HBV among Korean blood
donors and the sensitivity of enzyme immunoassay. The
residual risk during 2000 and June 2007 was calculatedwith the number of seroconvertors drawn from PPV.
The number of seroconvertors were adjusted by the dur-
ation using EIA and CLIA during the transition period.
Data were analyzed using a statistics package SPSS
20.0 (SPSS Inc., Illinois, USA). Poisson regression for
trend was used to evaluate the trend of residual risk for
HIV, HCV, and HBV across the period. A p-value of less
than 0.05 was considered statistically significant.
The total risk was calculated by summing the risks of
first-time donors and repeat donors. Each risk was
derived by multiplying the incidence rate of cases in
each window period. Each risk was then adjusted by the
corresponding percentage in all blood donations.
This study was approved by the Institutional Review
Board of the Korean Red Cross.
Results
From January 2000 to December 2010, Korean Red
Cross Blood Centers collected a total of 25,931,924
donations. Repeat donors accounted for 20,914,785
donations (80.7%). During the study period, a total of 43
HIV-positive (2004–2009), 139 HCV-positive (2000–
2009), 629 HBV-positive donors (2000–2009) were clas-
sified as seroconvertors (Table 3). The residual risk for
HCV decreased throughout the study period (p = 0.001).
The residual risk of HIV was estimated at 1 in 1,080,244
in 2004/2005 and at 1 in 1,813,998 in 2008/2009
(p = 0.745). The residual risk of HCV decreased continu-
ously from 1 in 81,431 in 2002/2001 to 1 in 4,560,879 in
2008/2009, which is extremely low like that of HIV. The
residual risk of HBV was estimated at 1 in 67,826 in
2008/2009 (p = 0.885), which is more than 20 times
higher than other viruses (Table 3). The incidence rates
among first-time and repeat donors were 1.0 and 2.0 for
both HIV and HCV (Tables 4 and 5). The most recent
(2009/2010) residual risk of transfusion-transmitted in-
fection in Korea was estimated to be 1 in 1,356,547
Table 3 Residual risk of transmitting viral infection by transfusing seronegative units donated from 2000 to 2010
2000-2001 2002-2003 2004-2005 2006-2007 2008-2009 p-value of Poisson
regression analysis
HIV
No. of seroconvertors - - 17 10 16
Incidence rate per 100,000 person-yr - - 1.99 1.31 1.83
(95% CI)* (0~8.30) (0~6.51) (0~7.81)
Residual risk (per 100,000 donations) - - 0.09 0.04 0.06 p = 0.745
(95% CI) (0~1.43) (0~0.95) (0~1.14)
RR (1 in) - - 1,080,244 2,534,406 1,813,998
HCV
No. of seroconvertors 64 31 23 14 7
Incidence rate per 100,000 person-yr 6.80 3.19 2.69 1.83 0.80
(95% CI) (0~18.34) (0~11.00) (0~10.02) (0~7.97) (0~4.76)
Residual risk (per 100,000 donations) 1.23 0.58 0.28 0.05 0.02 p = 0.001
(95% CI) (0~6.14) (0~3.91) (0~2.65) (0~1.07) (0~0.65)
RR (1 in) 81,431 173,611 357,197 1,991,405 4,560,879
HBV
No. of seroconvertors 126 121 105 175 105
Incidence rate per 100,000 person-yr 13.48 12.49 12.30 22.87 11.96
(95% CI) (0~29.73) (0~27.95) (0~27.98) (1.16~44.58) (0~27.25)
Residual risk (per 100,000 donations) 2.18 2.20 1.99 3.48 1.47 p = 0.885
(95% CI) (0~8.72) 0~8.69) (0~8.30) (0~11.95) (0~6.83)
RR (1 in) 45,891 49,515 50,218 28,754 67,826
*CI denotes confidence interval.
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43,666 for HBV (Table 6). The odds ratios for HIV,
HCV, and HBV positivity in first-time donors compared
to repeat donors in 2010 were 0.8, 11.8, and 19.6, re-
spectively (Table 7).
Discussion
A residual risk of transfusion-transmitted infection per-
sists despite the adoption of stricter donor selection cri-
teria and continuous improvements in the performance
of screening assays. This risk is mainly linked to dona-
tions in the window following a recent, undetectedTable 4 Incidence rate of HIV among first-time donors
and repeat donors
Incidence rate per 100,000 donations
Period First-time donors Repeat donors Total
2005-2006 1.0 2.1 1.2
2006-2007 0.6 1.3 0.8
2007-2008 0.7 1.5 0.9
2008-2009 0.9 1.8 1.1
2009-2010 1.2 2.4 1.4
Total 1.0 2.0 1.8infection. The residual risk of transmitting HIV, HCV, or
HBV during a blood transfusion was estimated between
2000 and 2010. An incidence/window period model was
used to estimate the residual risk. A mathematical model
to quantify viral nucleic acid concentrations was devel-
oped in the early 2000s, when most developed countries
began nucleic acid testing (NAT) for donations [11].
NAT for HIV and HCV in Korea was commenced in
February 2005. 10 HIV and 19 HCV NAT yield dona-
tions were identified between 2005 and 2010 among
14,246,270 donations. Since the average yield per year
was extremely low, the method of Schreiber was used inTable 5 Incidence rate of HCV among first-time donors
and repeat donors
Incidence rate per 100,000 donations
Period First-time donors Repeat donors Total
2005-2006 1.7 3.3 2.0
2006-2007 0.9 1.8 1.1
2007-2008 0.7 1.4 0.8
2008-2009 0.4 0.8 0.5
2009-2010 0.6 1.2 0.7
Total 1.0 2.0 1.8
Table 6 Most recent residual risk of transfusion-
transmitted infection, 2009 to 2010
HIV HCV HBV
No. of seroconvertors 22 11 167
Incidence rate per 100,000 person-yrs. 2.45 1.96 18.58
Residual risk per 100,000 donations 0.07 0.03 2.29
(95% CI) (0~1.13) (0~0.79) (0~8.90)
Residual risk (1 in ) 1,356,547 2,984,415 43,666
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dence density.
Residual risk estimates vary among countries, depend-
ing on the incidence rates among blood donors and the
tests used. Thus, some variations might reflect differ-
ences in the incidence and background prevalence, as
well as the testing methods used. NAT, which was intro-
duced to industrialized countries in the 1990s and
2000s, dropped the residual risk from 1 in 513,000 to 1
in 3,415,000 for HIV and from 1 in 149,000 to 1 in
1,935,000 for HCV [7,12-14]. The residual risks of HIV
and HCV for several countries have become immeasur-
ably small in recent years (approximately 1 infection per
1 to 2 million units) [15,16].
The HBV prevalence differs by geography [17]. The re-
sidual risk of HBV in countries with low prevalence
(<2%), such as the UK, was 1 in 296,736 (3.37 per mil-
lion donations) in the 1990s, and 1 in 729,927 (1.37 per
million donations) in the 2000s [18]. The residual risk of
HBV in countries with moderate to high prevalence
declined from 1 in 10,700 to 1 in 340,000 during a simi-
lar period [19,20]. Even though the probability of miss-
ing a donation infected with HBV has declined over
time, the residual risk of HBV is greater than the risks
for HIV and HCV.Table 7 Confirmed positive rate per 100,000 first-time
and repeat donors with HIV and HCV and repeat reactive
rate per 100,000 donors with HBV
2006 2007 2008 2009 2010
HIV First-time donor 1 3 2 1 1
Repeat donor 2 2 2 1 2
Odds ratio 0.4 1.8 1.4 0.8 0.8
HCV First-time donor 37 32 28 27 27
Repeat donor 5 4 3 3 2
Odds ratio 7.1 8.3 9.2 10.9 11.8
HBV First-time donor 672 588 512 451 396
Repeat donor 48 30 13 11 20
Odds ratio 14.0 19.3 38.6 41.4 19.6
Total First-time donor 710 622 542 479 424
Repeat donor 56 36 18 15 24
Odds ratio 12.8 17.4 29.9 32.2 17.5In this report, we determined the trend of incidence
rates and residual risks of infection in donations made
to Korean Blood Services through 2000 to 2010. The risk
of HCV in 2000/2001 decreased 56-fold by 2008/2009,
but those of HIV and HBV have not changed.
The residual risk for HIV did not change significantly.
It is due to the fact that the assay for HIV did not change
from 2005 to 2010, and the exclusion of donors with high
risk behaviors were not done completely. The current
risk level of HIV is comparable to developed countries. If
the risk of HIV needs to be reduced, other safety mea-
sures should be applied to completely exclude the donors
with risk behaviors. Blood safety regarding HCV has
improved immensely during the last decade due to the
implementation of NAT and improved performance of
serologic assays. The residual risk has decreased 31%
(95% CI, 20~56%) annually (data not shown).
Even though the residual risk for HBV in 2008/2009
has decreased 19.9-fold from that in 1995/1996 [21], the
risk for HBV did not change significantly during the last
decade. Even after using a more sensitive CLIA, the re-
sidual risk of HBV is still substantial. This can be gener-
ally explained by differences in infectivity, viral doubling
time, and minimum infectious dose. Practically, the rea-
son of the immaterial reduction of risk through the ap-
plication of CLIA is due to a comparatively small
reduction of window period. The reduction rate of win-
dow period was only 23.7% and the reduction of residual
risk was 32.3% from 2000/2001 to 2008/2009. The
current residual risk for HBV is more than 20-fold
higher than that for HIV and HCV, and approximately
5-fold higher than those in other countries with moder-
ate to high prevalence. That is why the introduction of
HBV-NAT is urgent in Korea and will commence in July
2012 nationwide. The residual risk of HBV will be effi-
ciently reduced through an individual HBV-NAT like
Spain, which has a similar prevalence of HBV [22]. How-
ever, HBsAg will remain as one of the mandatory tests
for blood screening after the implementation of HBV-
NAT, since Korea is an endemic area and dropping a
blood screening test is not an easy decision for govern-
mental officials.
Interestingly, the serial trend of residual risk showed
that the residual risks of all three viruses increased in
2009/2010 compared to the previous study period
(2008/2009). This phenomenon might be attributed to
the application of several strong incentive systems for
blood donors commenced in 2010 to secure the blood
supply. Approximately 80% of Korean blood donors are
in their 10s and 20s. The target population of donor re-
cruitment programs is usually young students. The Ko-
rean parents are excessively education-oriented, and the
students are extremely sensitive to the incentives related
to extra credit for school. In this situation, application of
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hinder the effective exclusion of donors with high risk
behaviors. Therefore, incentives especially for young
donors should be applied with discretion. Generally the
residual risk depends upon the prevalence and the sensi-
tivity of the test method (window period of the test).
However, other factors besides these two traditional typ-
ical factors could influence the actual residual risk.
Therefore, a continuous monitoring of residual risk is
critical in management of blood safety, even though the
same test method is continually used and the prevalence
of disease does not change. Even though the declining
trend of residual risk for HCV has stopped and
increased in 2009/2010 and residual risk for HIV in
2009/2010 was higher than that in 2008/2009, the
current residual risks for HIV and HCV do not substan-
tially differ from those of developed countries.
The assays have changed several times over the years
that data were analyzed. NAT was commenced in 2005
and the same reagents and the same instruments have
been used until 2010. Since the assay reagents and
instruments were maintained the same for more than
70-80% of blood donations, the change of assays does
not seem to affect the estimates significantly.
We adjusted the total residual risk for the incidence of
first-time donors. This estimate was based on the fact
that donor behavior was not affected during the window
period, but donors with an early acute infection with
subtle mild symptoms or a history of risky behavior
might delay the next donation. Thus, the residual risk
might be underestimated due to an inaccurate and smal-
ler number of seroconvertors among blood donors.
The incidence rates of HCV and HBV were higher
among first-time donors than repeat donors. The inci-
dence rates of HIV did not differ among first-time and
repeat donors. Some repeat donors with high-risk behav-
ior may not have answered the questionnaire honestly.
Our HIV findings differed from previous reports [16,23].
We did not include donors with chronic infection in
the risk assessment. Even though the infectivity from
donors with a chronic hepatitis C infection is 1,000
times weaker than from donors with an acute hepatitis
C infection, the donation from a donor with chronic
HCV can be infectious [24]. Likewise, low-level HBV
carriers and HBsAg mutant viruses were not considered
in our estimate of residual risk.
Our model does not reflect infectivity. A minimum in-
fectious dose might cause infectivity to differ during the
window period, but all donations during the window
period were assumed to be infectious.
Current data suggest that HIV is considerably less in-
fectious than HCV and HBV. A recent report shows that
100 to 10,000 copies of transmitted HIV RNA falls well
in the 0- to 100-percent infectivity range [25]. Literatureshows that less than 100 copies of HCV and HBV can
cause infection [26].
Recently, Busch et al introduced a new approach to es-
timate the duration of infectious window period, based
on back-extrapolation of acute viral replication dynamics
[27]. The NAT yield data for the last 6-year period
seemed to be large enough to apply an alternative
method, but the estimated window period of HCV NAT
was too long to accept. As Busch et al mentioned about
their limitation, the new method was based on the con-
cept that the incidence in donor population does not
change significantly, which was not fit in our situation.
There are multiple factors that could influence the re-
sidual risk other than the prevalence and the sensitivity
of screening assay. This phenomenon seems to be attrib-
uted to the unique cultural environment in Korea, such
as application of excessive pre-cautionary safety mea-
sures after the blood scandal in 2005. Using NAT screen-
ing data from large numbers of donations by a new
approach did not always guarantee an accurate estima-
tion of window period.
We may have overestimated the residual risk by assum-
ing that all window period donations were infectious. The
presence of virus in a donation does not imply that the re-
cipient was infected. The viral load may have been too
low, the infectivity may have been too weak, or the recipi-
ent might have been vaccinated.
Korea has a moderate to high risk of HBV [28].
HBsAg-positive rate reached 4.6% in Korean residents
aged 10 and older in 1998, and the prevalence dropped
gradually to 2.9% in 2010 [29]. However, the prevalence
of HBV is still substantially higher than those in other
developed countries. Since introducing the hepatitis B
virus vaccine in 1985, the prevalence of immunized resi-
dents aged 30 and older has reached 58.0%. One study
showed that the positive rate of anti-HBs was approxi-
mately 80% in young patients [30]. The universal vaccin-
ation of HBV since 1995 will contribute to the reduction
of residual risk of HBV in Korea. Thus, the actual trans-
mission of HBV from a transfusion is likely lower than
the estimated residual risk.
Conclusion
The residual risk of HCV declined over the last decade
due to improved screening reagents, implementation of
the nucleic acid amplification test, and tight application
of strict donor selection procedures. Current residual
risk estimates for HIV and HCV in Korea are extremely
low, but the risk for HBV is still high; therefore, urgent
measures should focus on decreasing the residual risk of
HBV. Despite the introduction of more sensitive assays
in blood screening, several other factors may influence
the actual residual risk of transfusion-transmitted infec-
tion. A continuous monitoring of residual risk of
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blood safety.
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